IL22 and inflammatory bowel disease: A key advantage of targeting IL-22 in IBD is that IL-22 receptors are primarily expressed on epithelial cells rather than immune cells, meaning that IL-22-based therapies can enhance tissue repair without directly suppressing systemic immune responses.